Skip to main content
TipRanks
Go Ultimate75% OFF

Immucell (ICCC) Q3 2026 Earnings Report

81 Followers

ICCC Q3 2026 EPS Results

Actual EPS
$0.10
Consensus EPS
―
Beat/Miss
―
One Year Ago EPS
-$0.02

ICCC Q3 2026 Revenue Results

Actual Revenue
$8.04M
Expected Revenue
―
Beat/Miss
―
YoY Revenue Growth
+46.02%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
After Close
Conference Call
Thursday, November 12, 2026
ICCC Upcoming Earnings

Immucell's next earnings date is estimated for February 23, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

ICCC Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:5.19%|
Earnings Call Sentiment|Positive

The call was strongly positive, characterized by 46% third-quarter revenue growth, improved gross margin, a return to profitability, higher manufacturing output, strong distributor and Tri-Shield growth, and progress on capacity expansion. The company also reported challenges, including historical contamination-related supply issues, rising colostrum-sourcing prices, higher operating expenses, and the unsuccessful Re-Tain development program, but these were outweighed by the reported operating and financial improvements.

Company Guidance

Management expects calf values to remain strong in 2027 and 2028, believes it can meet customer demand with improved yield management until the new drying capacity expansion project is completed, and expects the new freeze dryer planned for installation in the first half of 2027 to “triple or so” freeze-drying capacity; the liquids processing expansion is expected to be completed by the end of 2027, with the overall project remaining on track to the original $8 million overall budget.

  • Strong Third-Quarter Revenue GrowthThird-quarter 2026 product sales were approximately $8 million, up 46% compared with the third quarter of 2025. Management attributed the increase to restored product availability, a favorable domestic calf market, increased commercial activity, improved supply-chain management, and the absence of distributor restocking headwinds that affected the prior-year quarter.
  • Domestic and International Sales ExpansionDomestic third-quarter sales increased 29.2% year over year to $6.9 million, while international sales increased 573% to $1.1 million. Canada accounted for most of the international growth, helped substantially by the clearing of 2025 back orders.
  • Nine-Month Sales and Distributor Volume GrowthProduct sales for the first nine months of 2026 reached $25.6 million, an increase of 27.8% compared with the first nine months of 2025. Distributor volumes increased 23% year over year for the nine-month period and 18% in the third quarter.
  • Tri-Shield GrowthTri-Shield, the company's flagship product offering protection against neonatal diarrhea, achieved 32.1% growth during the first nine months of 2026. Management said higher calf values make it easier to discuss calf protection with producers and that the company remains focused on promoting Tri-Shield.
  • Gross Margin RecoveryThird-quarter gross margin was 44.2%, compared with 42.9% in the third quarter of 2025 and 33.9% in the second quarter of 2026. The year-over-year improvement primarily reflected higher pricing and improved manufacturing execution, while the sequential improvement was driven by increased manufacturing output across all departments, lower scrap, and greater benefits from product pricing.
  • Return to ProfitabilityThird-quarter net income was approximately $1 million, compared with a net loss of $140,000 in the third quarter of 2025. Net income for the first nine months of 2026 was $4.7 million, compared with $1.8 million in the same period last year.
  • Adjusted EBITDA ImprovementAdjusted EBITDA increased to $1.9 million in the third quarter of 2026 from $800,000 in the third quarter of 2025. For the first nine months, adjusted EBITDA was $7.3 million compared with $4.4 million in the prior-year period.
  • Improved Manufacturing OutputManufacturing output averaged approximately 435,000 manufacturing units per month during 2026, 14% higher than the 2025 average and substantially above the 252,000-unit monthly average in 2023 during the height of the contamination issues. Management cited yield-improvement projects, better bottleneck management, shift-schedule changes, and technology and equipment changes.
  • Capacity Expansion On TrackThe First Defense manufacturing capacity expansion remains on track within the original $8 million overall budget. The company had spent $1.7 million as of September 30, 2026, primarily on equipment. The freeze-drying expansion is expected to be completed in the first half of 2027, while the liquids-processing expansion is expected by the end of 2027.
  • Significant Freeze-Drying Capacity Increase PlannedThe company is adding one large freeze dryer that management said will produce more than the four currently operating freeze dryers combined. The new equipment is expected to roughly triple freeze-drying capacity and is intended to address the current drying bottleneck.
  • Strong Balance Sheet and Liquidity PositionAs of September 30, 2026, ImmuCell had $7.9 million of cash and $9.9 million of inventory, including approximately $3 million of finished goods inventory heading into its typically busy season. Working capital increased from $13 million at the end of 2025 to $16.9 million at the end of the third quarter.
  • Expanded Financing FlexibilityThe company is anticipating signing a new $3 million line of credit with a three-year term, replacing the previous $1 million one-year term line that expired in September. ImmuCell also notified its investment banking firm that it was terminating its unused at-the-market sales agreement, with no plans to use it in the future.
  • Favorable Calf-Market FundamentalsManagement said calf values have risen fivefold since 2021 and are expected to remain strong in 2027 and 2028 as tight cattle supplies support the market. The company said higher calf values and fewer dairy replacement heifers are increasing the priority placed on newborn calf health.
  • Commercial Team and Customer GrowthSince November 2025, the commercial team expanded from nine to 13 people. Quality sales calls increased significantly from the second to the third quarter, revenue per field sales representative grew year over year, new customers contributed approximately 46% of third-quarter net growth, and increased utilization by existing customers contributed the remaining 54%.
  • Functional Feed ProgressThe Functional Feed product line, developed for calf ranches, has already met its full-year targets. Management said the product has demonstrated 50% lower pre-weaning removal rates at customer operations and expressed optimism about further growth.
  • First Defense Market PositionManagement estimated that First Defense captures approximately 34% of U.S. spending on bovine scours biological products and said it was pleased with the product's premium positioning. The company also cited an unsolicited dairy-farmer endorsement reporting only three losses among 650 heifers born over seven months while using First Defense.
  • Supply-Chain and Colostrum-Sourcing InitiativesImmuCell hired a team leader for its farm team, developed a new value proposition for source farms, and began trials intended to improve yields from collected colostrum. Management said the new approach should improve colostrum sourcing and increase confidence in meeting future demand.
  • Lower Product Development SpendingProduct development expenses declined to approximately $175,000 in the third quarter of 2026 from approximately $700,000 in the third quarter of 2025, driven by reduced spending on Re-Tain development and the shift of certain former Re-Tain-related expenses to cost of goods sold.
  • Potential Aquaculture Licensing RevenueImmuCell entered into a minor licensing agreement with an aquaculture company for rights to use its intellectual property for certain marine species. Management said the agreement may generate future cash flows.

ICCC Earnings History

ICCC earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 23, 20272026 (Q4)―--0.32――
Nov 12, 20262026 (Q3)―0.10-0.01780.00% (+0.12)
Aug 13, 20262026 (Q2)―0.200.06257.14% (+0.14)
May 14, 20262026 (Q1)―0.210.1633.54% (+0.05)
Mar 04, 20262025 (Q4)―-0.320.06-643.10% (-0.37)
Nov 13, 20252025 (Q3)―-0.01-0.0982.56% (+0.07)
Aug 14, 20252025 (Q2)―0.06-0.2128.57% (+0.25)
May 14, 20252025 (Q1)―0.16-0.06387.50% (+0.22)
Feb 25, 20252024 (Q4)―0.06-0.15139.46% (+0.20)
Nov 13, 20242024 (Q3)―-0.09-0.1228.93% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed